Category: (canakinumab)

  • Strike two for Novartis’ lung cancer antibody canakinumab

    Expectations for Novartis’ canakinumab as a therapy for cancer have taken another dive, after a second phase 3 trial in non-small cell lung cancer (NSCLC) failed to meet its primary objectives. Novartis isn’t giving up on the programme yet, as it still has other trials of canakinumab in play, but the latest failure makes prospects […]

  • Novartis’ canakinumab falls short in phase 3 lung cancer trial

    Novartis’ attempt to treat cancer with the anti-inflammatory drug canakinumab was always a long shot, but it’s nevertheless a disappointing feeling when things don’t work out. Already approved for auto-inflammatory diseases such as active systemic juvenile idiopathic arthritis under the brand name Ilaris, Novartis is testing canakinumab to see if inhibiting the IL-1beta pathway can […]